CD BioGlyco is a leader in the field of glycomedicine development. Our team has developed a comprehensive glycomedicine development platform focused on solving difficulties and problems in glycomedicine research and development. We are confident to be your indispensable research assistant in the field of glycobiology.
According to the sources of carbohydrates, our services include plant-derived, animal-derived, microbial-derived, and synthetic carbohydrate-based glycomedicine development. Depending on the types of carbohydrates, our services include monosaccharide, disaccharide, trisaccharide, oligosaccharide, polysaccharide, glycoside, and glycopeptide-based glycomedicine development. Depending on the applications, we offer the development of anticoagulant, cardiovascular, antitumor, antidiabetic, antibacterial, antiviral, and antiparasitic glycomedicines. According to the strategies, we develop glycomedicine targeting the interaction of lectins and carbohydrates, targeting carbohydrates of specific pathogens, or targeting carbohydrate changes in diseases.
In addition, we also provide glycoengineering-based protein and antibody drug development services for global customers.
We provide isolation, purification, and characterization services of plant-derived carbohydrates, which are the basis for the development of plant-derived glycomedicine with tailored biological functions.
CD BioGlyco has accomulated extensive experience in modifing the polysaccharide groups of animal-derived carbohydrates such as chitosan, chondroitin, and hyaluronic acid to develop glycomedicine.
CD BioGlyco has developed various strategies for microbial-derived carbohydrate-based glycomedicine development, such as designing targeted block copolymers containing microbially derived carbohydrates.
Monosaccharides are important metabolic intermediates and biomarkers. CD BioGlyco has established a specialized platform for the development of monosaccharide-based glycomedicines.
CD BioGlyco has been focusing on the glycomedicine research for many years, providing customers with the design and synthesis services of disaccharide-based glycomedicine.
CD BioGlyco has a professional and first-class research team to help solve customers' problems in the development of trisaccharide-based glycomedicine.
CD BioGlyco designs glycomedicine according to each specific customers' requirement, and chemically or enzymatically synthesizes well-defined oligosaccharides and performs structural analysis.
As a leading provider in the field of glycobiology, CD BioGlyco offers chemical and enzymatic modification of natural polysaccharides as well as customization services of non-natural polysaccharide analogs.
CD BioGlyco provides glycosides-based glycomedicine development services, such as chemical synthesis of natural glycosides and their artificial analogs, and determination of glycoside activity.
CD BioGlyco has developed a special platform for glycomedicine based on N-glycopeptide and O-glycopeptide to solve the problems and difficulties encountered by customers in the development.
CD BioGlyco has one-stop services for the synthesis, modification, analysis, and activity detection of carbohydrate-based anticoagulants glycomedicines. Welcome global researchers to cooperate with us!
CD BioGlyco provides carbohydrate-based cardiovascular glycomedicine development and activity determination services for our clients worldwide. Welcome global researchers to cooperate with us!
The professional team and experienced scientists of CD BioGlyco provide global customers with in vitro and in vivo antitumor activity screening services of glycomedicine.
As a leader in the field of glycomedicine, CD BioGlyco not only customizes the development of carbohydrate-based antidiabetic glycomedicine for customers, but also helps customers evaluate the activity of glycomedicines.
CD BioGlyco provides synthesis and antibacterial activity testing services for aminoglycosides, nucleosides, macrolides and glycopeptides based antibacterial glycomedicines.
CD BioGlyco provides carbohydrate modification, carbohydrate-based antiviral glycomedicine synthesis, and antiviral glycomedicine bioactivity screening services.
According to the needs of customers, we develop glycomedicines with high inhibitory activity on the interaction between carbohydrates and lectins.
Since the microbes that cause infections often contain different carbohydrates than humans, it is needed to develop glycomedicines specifically targeting carbohydrates of different pathogens.
In recent years, more and more researchers have utilized the function of carbohydrates to develop biopharmaceuticals. CD BioGlyco develops protein and antibody drugs by modifying carbohydrates with Glycoengineering methods.
CD BioGlyco is committed to providing high-quality carbohydrate-based glycomedicine development services. If you have special needs in glycomedicine development, please feel free to contact us for more information.